ArticleObesity (Silver Spring, Md.)2014
Cord blood levels of osteopontin as a phenotype marker of gestational age and neonatal morbidities.
Article in Obesity (Silver Spring, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Osteopontin: Its Properties, Recent Studies, and Potential Applications.International journal of molecular sciences · 2025Review
- An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy.Frontiers in nutrition · 2024Review
- Association between prenatal socioeconomic disadvantage, adverse birth outcomes, and inflammatory response at birth.Psychoneuroendocrinology · 2023Article
- Cord blood adiponectin and leptin are associated with a lower risk of stunting during infancy.Scientific reports · 2022Article
- The Patent Ductus Arteriosus in Extremely Preterm Neonates Is More than a Hemodynamic Challenge: New Molecular Insights.Biomolecules · 2022Article
- Osteopontin and malaria: no direct effect on parasite growth, but correlation with P. falciparum-specific B cells and BAFF in a malaria endemic area.BMC microbiology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesOsteopontin (OPN) is a proinflammatory cytokine associated with metabolic syndrome. Extreme birth weight categories including small for gestational age (SGA), and large for gestational age (LGA) are risk factors for metabolic syndrome. However normal levels of plasma OPN in neonates and the relationship of OPN to fetal growth remain unknown. We evaluated the association of umbilical cord blood OPN with gestational age, birth weight, and neonatal outcomes.
methodsA cross-sectional study of 261 newborns of all gestational ages beginning at week 26, and 26 adults for comparison was performed. Umbilical cord blood from newborns and analyzed plasma for OPN by ELISA was collected.
resultsPlasma OPN was significantly higher in neonates (414.65 ± 136.72 ng/mL) compared to adults (33.37 ± 14.66 ng/mL, P < 0.001). There was an inverse correlation between OPN and gestational age (r = -0.48, P < 0.0001). LGA infants had lower OPN than appropriate for gestational age (AGA) infants, but LGA was not an independent predictor of OPN in multivariate analysis. Among preterm infants, patent ductus arteriosus (PDA) was independently associated with higher OPN (OR = 2.49, P = 0.02).
conclusionOur results raise the possibility that OPN has a physiologic role in fetal growth and development, and may be a useful biomarker for PDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.